目的：探究Paul青光眼植入物(PGI)在短期随访期间的安全性和有效性，分享新型房水引流装置在印度尼西亚人群中应用的首次经验。

方法：回顾性分析2022-04/2022-12期间使用PGI植入物的患者21例22眼，随访至少2mo。主要结局指标为手术失败，定义为眼压(IOP)超过21mmHg，或连续2次就诊较基线水平降低小于20%，需行其他青光眼手术或移除植入物。

结果：纳入患者的随访时间为2-6mo，平均IOP降低52.27±22.94%(9-90)%，总体成功率为59%，有青光眼手术史和未接受过青光眼手术的患者手术完全成功率分别为50%和59%。并发症有复视(2例)、早期低眼压(1例)、前房积血(1例)及引流管暴露(2例)。

结论：植入PGI的完全成功率为57%。未发生严重术后并发症，低眼压术后早期消退1例。

METHODS: A total of 21 patients(22 eyes)with PGI implants from April 2022 to December 2022 and with at least a complete 2mo follow-up were retrospectively analyzed. The primary outcome measure was failure, defined as intraocular pressure(IOP)out of the target range of 21 mmHg or less than 20% reduction from baseline for 2 consecutive visits, other glaucoma surgeries required, or removal of the implant.

RESULTS: The follow-up period was 2 to 6mo. The mean IOP reduction was 52.27±22.94%, with a range of 9% to 90%. The complete success rate was 59%, and patients with or without a history of glaucoma surgery had 50% and 59% of complete success rates, respectively. Complications of the surgery were diplopia(n=2), early hypotony(n=1), hyphema(n=1), and exposed tube(n=2).

CONCLUSION: The complete success of the PGI implantation was 57%. No serious postoperative complications were found in our cases. One case of hypotony resolved in the early postoperative period.